Axsome Therapeutics (AXSM) Receivables: 2022-2025
Historic Receivables for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $215.8 million.
- Axsome Therapeutics' Receivables rose 55.97% to $215.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $766.2 million, marking a year-over-year increase of 54.98%. This contributed to the annual value of $155.5 million for FY2024, which is 44.90% up from last year.
- Axsome Therapeutics' Receivables amounted to $215.8 million in Q3 2025, which was down 1.28% from $218.6 million recorded in Q2 2025.
- Axsome Therapeutics' Receivables' 5-year high stood at $218.6 million during Q2 2025, with a 5-year trough of $16.2 million in Q2 2022.
- Over the past 3 years, Axsome Therapeutics' median Receivables value was $133.5 million (recorded in 2024), while the average stood at $135.4 million.
- Data for Axsome Therapeutics' Receivables shows a peak YoY soared of 413.75% (in 2023) over the last 5 years.
- Quarterly analysis of 4 years shows Axsome Therapeutics' Receivables stood at $46.8 million in 2022, then skyrocketed by 129.34% to $107.3 million in 2023, then surged by 44.90% to $155.5 million in 2024, then skyrocketed by 55.97% to $215.8 million in 2025.
- Its Receivables was $215.8 million in Q3 2025, compared to $218.6 million in Q2 2025 and $176.2 million in Q1 2025.